Regeneron Pharmaceuticals, Inc. ( REGN) TD Cowen 46th Annual Health Care Conference March 4, 2026 9:10 AM EST Good morning, everyone. Tyler Van Buren here, senior biotech analyst at TD Cowen. Thank ...
The FDA has approved Dupixent (dupilumab) for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis.
Merck’s Keytruda will soon lose exclusivity, just as weight-loss giants Eli Lilly and Novo Nordisk press in with their blockbuster GLP-1s.
If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged 2 to 11 years with CSU inadequately controlled by standard-of-care antihistamine treatment CSU is a chr ...
Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.
People with allergic fungal rhinosinusitis taking Dupixent (dupilumab) saw significant improvement in congestion and sinus ...
The FDA approved Dupixent as the first treatment for allergic fungal rhinosinusitis in adults and children over six years old ...
US FDA approves Sanofi and Regeneron’s Dupixent for allergic fungal rhinosinusitis: Paris Thursday, February 26, 2026, 15:00 Hrs [IST] The US Food and Drug Administration (FDA) ...
The approval makes Dupixent the first FDA-approved therapy for allergic fungal rhinosinusitis, supported by Phase III data showing significant improvements in sinus opacification, nasal symptoms, and ...
The FDA approved dupilumab (Dupixent) for treating allergic fungal rhinosinusitis, a first for the condition, the agency announced on Wednesday. Approval stipulates use in individuals 6 years and ...
The FDA has approved dupilumab to treat allergic fungal rhinosinusitis in adults and children ages 6 years and older.
Located at 210 Princess St., 210 Gallery is operated by the Manitoba Arts Network and showcases the work of artists from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results